BiondVax Pharmaceuticals Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVXV research report →
Companywww.biondvax.com
BiondVax Pharmaceuticals Ltd. , a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
- CEO
- Amir Reichman
- IPO
- 2015
- Employees
- 33
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $4.97M
- P/E
- -19.26
- P/S
- 0.00
- P/B
- -5.81
- EV/EBITDA
- -2.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -4.92%
- ROIC
- -4.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-531,000 · 98.95%
- EPS
- $-0.20 · 99.44%
- Op Income
- $-11,061,000
- FCF YoY
- 67.48%
Performance & Tape
- 52W High
- $11.49
- 52W Low
- $0.63
- 50D MA
- $1.17
- 200D MA
- $1.79
- Beta
- 2.37
- Avg Volume
- 38.94K
Get TickerSpark's AI analysis on BVXV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 23 | MARGOLIN YAEL | other | 133,200 |
| Jan 1, 23 | MARGOLIN YAEL | other | 0 |
| Jan 1, 23 | Laster Morris C | other | 133,200 |
| Jan 1, 23 | Laster Morris C | other | 0 |
| Jan 1, 23 | Lowell George | other | 1,000,000 |
| Jan 1, 23 | Rotman Avner | other | 133,200 |
| Jan 1, 23 | Rotman Avner | other | 0 |
| Jan 1, 23 | Rotman Avner | other | 0 |
| Jan 1, 23 | Moed Samuel J | other | 3,280,000 |
| Jan 1, 23 | Green Jay | other | 1,000,000 |
Our BVXV Coverage
We haven't published any research on BVXV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BVXV Report →